Neuromidin (ipidacrine hydrochloride) tablets 20 mg. №50

Description

Neuromidin composition                                                                                                                                                    active substance: ipidacrine;
1 tablet contains ipidacrine hydrochloride 20 mg;
excipients: lactose monohydrate; potato starch; calcium stearate.

Release form
Tablets.

Indications
Neuromidin is used in the treatment of diseases of the peripheral nervous system such as polyneuritis, neuritis, polyneuropathy, myelopolyradiculoneuritis and myasthenia gravis. It is used to eliminate memory impairments of various origins, mental retardation in children, intestinal atony, bulbar paralysis and paresis, weakness of labor, impaired cerebral circulation. In addition, Neuromidin is successfully used in the complex therapy of craniocerebral trauma and multiple sclerosis.

Contraindications
Neuromidin is not prescribed for patients with hypersensitivity to ipidacrine, marked decrease in heart rate, bronchial asthma, epilepsy, angina pectoris, lesions of the vestibular apparatus, erosive and ulcerative lesions of the stomach and intestines. Neuromidin is not used in the therapy of pregnant women and women at the stage of lactation, and, in addition, the drug in the form of a solution for injection is unacceptable to use in the treatment of children under 14 years of age.

Children
The drug can be used in children over 12 years of age.

Application during pregnancy and lactation
Neuromidin is not used in the treatment of pregnant women, as studies have shown that it is able to penetrate the placental barrier and increase the risk of premature birth. However, it is actively used with weak labor. The drug penetrates into breast milk, which does not allow its use in the treatment of women at the stage of lactation.

Neuromidine tablets should be used orally.

• With neuritis – 1 tablet 2-3 times a day. The course of treatment – from 10-15 days for acute neuritis, to 20-30 days for chronic neuritis. If necessary, repeat the course of treatment 2-3 times with an interval of 2-4 weeks to achieve maximum effect.
• With myelopolyradiculoneuritis and paresis – 1 tablet 2-3 times a day for 30-40 days. Repeat the course of treatment repeatedly with an interval of 1-2 months. Repeat the course of treatment until the therapeutic effect is achieved.
• With myasthenia and myasthenic syndromes – 1-2 tablets 2-3 times a day. In severe forms, the dose can be increased to 200 mg per day (2 tablets 5 times a day in 2-3 hours). Course treatment, alternately with classic anticholinesterase drugs.
• With multiple sclerosis and other forms of demyelinating diseases of the nervous system, bulbar paralysis – 1 tablet 3-5 times a day for 60 days 2-3 times a year.
• In Alzheimer’s disease and other forms of senile mental disorders, start with a dose of 1-2 tablets per day, divided into 2 doses, with a gradual increase in dose by 2 tablets per week to 6-10 tablets per day (2 tablets 3-5 times a day). ). Duration of treatment – from 4 months to 1 year. Course therapy is possible – for 4-5 months with a break of 1-2 months.
• In organic lesions of the CNS, accompanied by movement disorders – 1 tablet 2-3 times a day. The average course of treatment is 30 days. If necessary, the course of treatment can be repeated.
• With intestinal atony – from 1 to 3 tablets per day, dividing the dose into 3 doses. The course of treatment is 1-3 weeks.
• Children over 12 years of age with mental retardation and diseases of the peripheral nervous system Neuromidin should be prescribed 1 tablet (20 mg) 2-3 times a day. The course of treatment is 1-2 months, depending on the clinical picture.

Overdose
With an acute overdose of Neuromidin, patients develop a state of cholinergic crisis, characterized by increased secretion of glands, bronchospasm, pupillary constriction, spontaneous urination and defecation, decreased heart rate, decreased blood pressure, convulsions, weakness and coma.

In case of an overdose of the drug, the administration of Atropine sulfate is indicated.

Side effects
When taking the drug, it is possible to develop dizziness, dyspeptic disorders, increased salivation and sweating, itching and rash, bradycardia and bronchospasm. If there are side effects, it is recommended to reduce the dosage of the drug with a break in treatment from 1 to 2 days.

Storage conditions and periods
The shelf life of tablets is 3 years, in a solution for injection – 2 years.